高强度超声聚焦刀联合FOLFOX4方案治疗晚期胰腺癌的临床观察

目的：探讨高强度超声聚焦刀联合FOLFOX4方案治疗晚期胰腺癌的疗效及安全性。方法60例晚期胰腺癌患者根据所采取的治疗方式分为治疗组32例和对照组28例，两组均行FOLFOX4方案化疗，治疗组联合高强度超声聚焦刀治疗。比较两组疗效、不良反应、疼痛缓解情况及无病生存时间（PFS）。结果6治疗组和对照组的有效率（RR）分别为28.1%和7.1%，疾病控制率（DCR）分别为71.9%和35.7%，治疗组高于对照组，差异有统计学意义（P﹤0.05）。治疗组的疼痛缓解率为53.1%（17/32），高于对照组的21.4%（6/28），差异有统计学意义（P﹤0.05）。治疗组的中位PFS为6.1个月，长于对照组的2.8个月，差异有统计学意义（P﹤0.05）。两组治疗最常见的不良反应为血液学毒性、恶心呕吐、神经毒性，但两组比较差异均无统计学意义（P﹥0.05）。结论高强度超声聚焦刀联合FOLFOX4方案治疗晚期胰腺癌的疗效较好，不良反应可耐受，值得临床应用。

Clinical observation of high intensity focused ultrasound combined with FOLFOX4 in the treatment of advanced pancreatic carcinoma

Objective To evaluate the efficacy and safety of high intensity focused ultrasound (HIFU) combined with FOLFOX4 in the treatment of advanced pancreatic carcinoma. Method Sixty patients with advanced pancreatic carcino-ma were enrolled in this study, and were divied into study group (n=32) or control group (n=28) according to treatment modality, FOLFOX4 was administered in both groups, while the study group was given additional HIFU. The efficacy, ad-verse reactions, pain relief and progression-free survival (PFS) were compared between the two groups. Result The re-sponse rate (RR) of the study group and control group was 28.1%and 7.1%, the disease control rate (DCR) was 71.9%and 35.7%, and both were significantly higher in the study group (P<0.05). The study group had a pain relief rate of 53.1%(17/32), which was higher than that of the control group at 21.4%(6/28), with significant difference observed (P<0.05). The median PFS of the study group was 6.1 months, longer than that in the control group at 2.8 months, and the dif-ference was statistically significant (P<0.05). The most common adverse reactions were hematological toxicity, nausea and vomiting, and neurotoxicity, of which the incidences were similar between the two groups (P>0.05). Conclusion High intensity focused ultrasound combined with FOLFOX4 is quite effectiveand well tolerated in the treatment of ad-vanced pancreatic carcinoma, and is worthy of clinical application.